Larkin JM - Search Results

1

Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies.

Chowdhury S, Larkin JM, Gore ME. Chowdhury S, et al. Among authors: larkin jm. Eur J Cancer. 2008 Oct;44(15):2152-61. doi: 10.1016/j.ejca.2008.06.028. Epub 2008 Sep 29. Eur J Cancer. 2008. PMID: 18829302 Review.

2

Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidence.

Kolomainen DF, Larkin JM, Badran M, A'Hern RP, King DM, Fisher C, Bridges JE, Blake PR, Barton DP, Shepherd JH, Kaye SB, Gore ME. Kolomainen DF, et al. Among authors: larkin jm. J Clin Oncol. 2002 Feb 15;20(4):982-6. doi: 10.1200/JCO.2002.20.4.982. J Clin Oncol. 2002. PMID: 11844820

3

The MRC randomised-controlled trial of interferon-alpha, interleukin-2 and 5-fluorouracil vs interferon-alpha alone in patients with advanced renal cell carcinoma (RE04): rationale and progress.

Larkin JM, Gore ME. Larkin JM, et al. Clin Oncol (R Coll Radiol). 2005 Aug;17(5):319-21. doi: 10.1016/j.clon.2005.03.007. Clin Oncol (R Coll Radiol). 2005. PMID: 16097560 No abstract available.

4

Anti-alphaGal-dependent complement-mediated cytotoxicity in metastatic melanoma.

Larkin JM, Norsworthy PJ, A'Hern RP, Eisen TG, Gore ME, Porter CD. Larkin JM, et al. Melanoma Res. 2006 Apr;16(2):157-63. doi: 10.1097/01.cmr.0000200490.62723.b0. Melanoma Res. 2006. PMID: 16567971

5

Kinase inhibitors in the treatment of renal cell carcinoma.

Larkin JM, Eisen T. Larkin JM, et al. Crit Rev Oncol Hematol. 2006 Dec;60(3):216-26. doi: 10.1016/j.critrevonc.2006.06.008. Epub 2006 Jul 24. Crit Rev Oncol Hematol. 2006. PMID: 16860997 Review.

6

A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma.

Larkin JM, Hughes SA, Beirne DA, Patel PM, Gibbens IM, Bate SC, Thomas K, Eisen TG, Gore ME. Larkin JM, et al. Br J Cancer. 2007 Jan 15;96(1):44-8. doi: 10.1038/sj.bjc.6603503. Epub 2006 Dec 5. Br J Cancer. 2007. PMID: 17146474 Free PMC article. Clinical Trial.

7

Expression of p16, CD95, CD95L and Helix pomatia agglutinin in relapsing and nonrelapsing very thin melanoma.

Fearfield LA, Larkin JM, Rowe A, A'Hern R, Fisher C, Francis N, MacKie R, McCann B, Gore ME, Bunker CB. Fearfield LA, et al. Among authors: larkin jm. Br J Dermatol. 2007 Mar;156(3):440-7. doi: 10.1111/j.1365-2133.2006.07581.x. Br J Dermatol. 2007. PMID: 17300231

8

Drug insight: advances in renal cell carcinoma and the role of targeted therapies.

Larkin JM, Chowdhury S, Gore ME. Larkin JM, et al. Nat Clin Pract Oncol. 2007 Aug;4(8):470-9. doi: 10.1038/ncponc0901. Nat Clin Pract Oncol. 2007. PMID: 17657252 Review.

9

Malignant melanoma (metastatic).

Larkin J, Gore M. Larkin J, et al. BMJ Clin Evid. 2008 Aug 22;2008:1718. BMJ Clin Evid. 2008. PMID: 19445806 Free PMC article. Review.

10

Combination systemic therapy for advanced renal cell carcinoma.

Miller RE, Larkin JM. Miller RE, et al. Among authors: larkin jm. Oncologist. 2009 Dec;14(12):1218-24. doi: 10.1634/theoncologist.2009-0105. Epub 2009 Nov 25. Oncologist. 2009. PMID: 19939892 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

420 results

Search Page

Filters